CCA
BHVN

Catalyst Capital Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Catalyst Capital Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-270
Closed -$10K – 527
2017
Q3 		$10K Hold
270
– – ﹤0.01% 367
2017
Q2 		$7K Buy
+270
New +$6.22K ﹤0.01% 429

Other funds holding BHVN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Catalyst Capital Advisors's BHVN Position: Q4 2017 in Review

Catalyst Capital Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2017, closing a stake of 270 shares — an estimated $10K sold.

Catalyst Capital Advisors first reported a position in BHVN in Q2 2017 and held it in 2 quarters. The position peaked at $10K in Q3 2017. 90 funds tracked by Wall St. Rank hold BHVN as of Q4 2017.

  • Catalyst Capital Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2017 after selling out during the quarter.
  • Catalyst Capital Advisors sold 270 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2017, an estimated $10K.
  • Catalyst Capital Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 2 quarters.
  • Catalyst Capital Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $10K in Q3 2017.
  • 90 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2017.

Based on Catalyst Capital Advisors's 13F filing for Q4 2017, filed 8 Feb 2018.